Journal of Chest Surgery

The Korean Society for Thoracic and Cardiovascular Surgery (대한심장혈관흉부외과학회)
권호 표지

Prognostic Factors of Thymic Carcinoma

흉선암의 예후인자

  • Park, In-Kyu (Department of Thoracic and cardiovascular Surgery, Yonsei University College of Medicine) ;
  • Kim, Dae-Joon (Department of Thoracic and cardiovascular Surgery, Yonsei University College of Medicine) ;
  • Kim, Kil-Dong (Department of Thoracic and cardiovascular Surgery, Eulji University College of Medicine) ;
  • Bae, Mi-Kyung (Department of Thoracic and cardiovascular Surgery, Yonsei University College of Medicine) ;
  • Chung, Kyung-Young (Department of Thoracic and cardiovascular Surgery, Yonsei University College of Medicine)
  • 박인규 (연세대학교 의과대학 흉부외과학교실) ;
  • 김대준 (연세대학교 의과대학 흉부외과학교실) ;
  • 김길동 (을지대학교 의과대학 흉부외과학교실) ;
  • 배미경 (연세대학교 의과대학 흉부외과학교실) ;
  • 정경영 (연세대학교 의과대학 흉부외과학교실)
  • Published : 2005.08.01
Download PDF
⟨ Previous Next ⟩

Abstract

Background: Thymic carcinoma is a rare malignant disease with sparse data for treatment and prognosis. We intended to investigate the prognostic factors of thymic carcinoma. Material and Method: Data of 42 patients, who were diagnosed and treated for thymic carcinoma from January of 1986 to August of 2003 were reviewed retrospectively. Influences of characteristics of patients, Masaoka stage, histologic grade, completeness of resection and adjuvant treatment on survival were evaluated. Result: There were 30 male and 12 female patients and their mean age was $52.0\pm15.7$ years old. There were 28 patients with low-grade histology and 13 patients with high-grade histology. Clinical stage according to Masaoka stage were I in 2, II in 2, III in 15 $(35.7\%)$, IVa in 10 $(23.8\%),\;and\;IVb\;in\;13\;(31\%)$ patients. Surgical resection was done in 22 patients, Complete resection was possible in 13 patients and incomplete resection was done in 9 patients. Among 20 patients without resection, 8 patients received chemotherapy, 7 patients received radiotherapy and 5 patients received combined therapy. Median survival time was $31.7\pm6.1$ months and 5 year survival rate was $28.5\%$. High grade histology (hazard ratio=3.009, $95\%\;confidence\;interval=1.178\sim7.685,$ p=0.021) and incompleteness of resection (hazard ratio=3.605, $95\%$ confidence interval= $1.1541\sim1.580$, p=0.023) were the prognostic factors of thymic carcinoma. Conclusion: In thymic carcinoma, low grade histology is a good prognostic factor and complete resection can prolong the survival of patients.

배경: 흉선암은 악성 종양으로 드문 질환이기 때문에 치료와 예후에 대한 자료가 충분치 않은 상태이다. 저자들은 흉선암 환자의 생존에 영향을 미치는 예후 인자들을 알아보고자 하였다. 대상 및 방법: 1986년 1월 1일부터 2003년 8월 31일까지 흉선암으로 치료받은 42명의 환자를 대상으로 임상특성, Masaoka병기, 조직학적 등급, 완전절제여부 및 보조요법 등과 생존율의 관계를 후향적으로 조사하였다. 걸과: 평균연령은 $52.0\pm15.7$세였고, 남자가 30명, 여자가 12명이었다. 조직학적 저등급(low-grade histology)군이 28명$(66.7\%)$, 고등급(high-grade histology)군이 13명 $(31\%)$이 었고, 세침흡인검사를 시행한 1예에서는 세포유형을 판별할 수 없었다. Masaoka 병기는 I기 2명, II기 2명, III기 15명$(35.7\%)$, IVa기 10명$(23.8\%)$, IVb기 13명$(31.0\%)$이었다. 수술은 22명에서 시행되었으며, 이 중 13명$(59\%)$에서 완전절 제가 가능하였다 수술 받지 않은 환자 20명 중 8명은 항암화학 요법, 7명은 방사선 치료, 5명은 두가지 치료를 병행하였다. 중앙생존기간은 $31.7\pm6.1$개월이었고, 5년 생존율은 $28.6\%$이었다. 다변량 분석 결과 조직학적 고등급군(위험도=3.009, $95\%$ 신뢰군간=$1:178\sim7.685$, p=0.021)과 불완전절제(위험도=$3.605,\;95\%$ 신뢰군간=$1.154\sim11.580$, p=0.023)가 예후에 영향을 미치는 인자로 나타났다. 걸론: 흉선암 환자에서 조직학적 저등급군이 예후가 좋았으며, 완전 절제로 생존율을 높일 수 있으리라 생각한다.

Keywords

References

  1. Detterbeck FC, Parsons AM. Thymic tumors. Ann Thorac Surg 2004;77:1860-9 https://doi.org/10.1016/j.athoracsur.2003.10.001
  2. Chung DA. Thymic carcinoma - analysis of nineteen clinicopathological studies. Thorac Cardiov Surg 2000;48:114-9 https://doi.org/10.1055/s-2000-9868
  3. Suster S, Rosai J. Thymic carcinoma-a clinicopathologic study of 60 cases. Cancer 1991;67:1025-32 https://doi.org/10.1002/1097-0142(19910215)67:4<1025::AID-CNCR2820670427>3.0.CO;2-F
  4. Masaoka A, Monden Y, Nakahara K, Tanioka T. Follow up study of thymomas with special reference to their clinical stages. Cancer 1981;48:2485-2492 https://doi.org/10.1002/1097-0142(19811201)48:11<2485::AID-CNCR2820481123>3.0.CO;2-R
  5. Blumberg D, Burt ME, Bains MS, et al. Thymic carcinoma: current staging does not predict prognosis. J Thorac Cardiovasc Surg 1998;115:303-9 https://doi.org/10.1016/S0022-5223(98)70273-9
  6. Kondo K, Monden Y. Therapy for thymic epithelial tumors: a clinical study of 1,320 patinets from Japan. Ann Thorac Surg 2003;76:878-85 https://doi.org/10.1016/S0003-4975(03)00555-1
  7. Yamakawa Y, Masaoka A, Hashimoto T, et al. A tentative tumor-node-metastasis classification of thymoma. Cancer 1991;68:1984-7 https://doi.org/10.1002/1097-0142(19911101)68:9<1984::AID-CNCR2820680923>3.0.CO;2-P
  8. Lucchi M, Mussi A, Basolo F, Ambrogi MC, Fontanini G, Angeletti CA. The multimodality treatment of thymic carcinoma. Eur J Cardiothorac Surg 2001;19:566-9 https://doi.org/10.1016/S1010-7940(01)00666-2
  9. Koizmi T, Takabayashi Y, Yamagishi S, et al. Chemotherapy for advanced thymic carcinoma. Am J Clin Oncol 2002;25: 266-268 https://doi.org/10.1097/00000421-200206000-00012
  10. Hsu HC, Huang EY, Wang CJ, Sun LM, Chen HC. Postoperative radiotherapy in thymic carcinoma: treatment results and prognostic factors. Int J Radiat Oncol Biol Phys 2002; 52:801-5 https://doi.org/10.1016/S0360-3016(01)02656-6
  11. Ogawa K, Toita T, Uno T, et al. Treatment and prognosis of thymic carcinoma-a retrospective analysis of 40 cases. Cancer 2002;94:3115-9 https://doi.org/10.1002/cncr.10588
  12. Liu HC, Hsu WH, Chen YJ, et al. Primary thymic carcinoma. Ann Thorac Surg 2002;73:1076-81 https://doi.org/10.1016/S0003-4975(01)03607-4
  13. Tsuchiya R, Koga K, Matsuno Y, et al. Thymic carcinoma: proposal for pathological TNM staging. Pathol Int 1994;44: 505 https://doi.org/10.1111/j.1440-1827.1994.tb02600.x
  14. Kondo K, Monden Y. Lymphogenous and hematogenous metastasis of thymic epithelial tumors. Ann Thorac Surg 2003; 76:1859-65 https://doi.org/10.1016/S0003-4975(03)01017-8
  15. Ahn JS, Park CK, Park NH, et al. Clinical analysis of thymic carcinoma. Korean J Thorac Cardiovasc Surg 2001;34: 162-6
  16. Takeda S, Sawabata N, Inoue M, Koma M, Maeda H, Hirano H. Thymic carcinoma. Clinical institutional experience with 15 patients. Eur J Cardiothorac Surg 2004;26:401-6 https://doi.org/10.1016/j.ejcts.2004.03.043
  17. Hsu CP. Chen CY, Chen CL, et al. Thymic carcinoma. Ten years experience in twenty patients. J Thorac Cadiovasc Surg 1994;107:615-20
  18. Hernandex-Ilizaliturri FJ, Tan D, Cipolla D, Connolly G, Debb G, Ramnath N. Multimordality therapy for thymic carcinoma. Am J Clin Oncol 2004;27:68-72 https://doi.org/10.1097/01.coc.0000046301.83671.09
  19. Tseng YL, Wang ST, Wu MH, Lin MY, Lai WW, Cheng FF. Thymic carcinoma: involvement of great vessels indicates poor prognosis. Ann Thorac Surg 2003;76:1041-5 https://doi.org/10.1016/S0003-4975(03)00831-2